Inquiry Basket
Loading ......
The gut is more than a digestive organ. It is one of the body's largest interfaces with the external environment and contains a complex ecosystem of microorganisms that continuously interacts with intestinal epithelial cells and immune cells. Within this environment, 25-hydroxyvitamin D [25(OH)D], the major circulating form of vitamin D, has emerged as an important factor connecting nutritional status, microbial ecology, intestinal barrier function, and immune regulation. The relationship is not simply a matter of vitamin D influencing gut bacteria. Increasing evidence suggests a bidirectional interaction: vitamin D signaling can shape the intestinal microbiota and mucosal immune environment, while gut microorganisms may influence vitamin D metabolism and host vitamin D signaling. Understanding this relationship provides a useful framework for studying inflammatory bowel disease (IBD), intestinal barrier dysfunction, chronic inflammation, and other conditions in which microbiota and immune regulation become disturbed.
Vitamin D undergoes several metabolic steps before exerting its major biological effects. Vitamin D obtained from sunlight, food, or supplements is first converted in the liver to 25(OH)D₃, which is the principal circulating form and is commonly used to assess vitamin D status. A second hydroxylation step converts 25(OH)D into 1,25-dihydroxyvitamin D [1,25(OH)2D], the biologically active form. Although the kidney is an important site of this conversion, the enzyme CYP27B1, or 1α-hydroxylase, is also expressed in several extra-renal tissues, including cells involved in mucosal immune responses. The active metabolite binds to the vitamin D receptor (VDR). VDR can form a complex with retinoid X receptor and regulate vitamin D-responsive genes. In intestinal and immune cells, this signaling network influences antimicrobial peptides, epithelial integrity, innate immune recognition, and inflammatory responses.
One important consequence is regulation of antimicrobial defense. Vitamin D signaling can promote the expression of antimicrobial peptides such as β-defensin 2, helping the intestinal mucosa respond to potentially harmful microorganisms while supporting an environment in which commensal bacteria can coexist with the host. Vitamin D signaling also affects immune-cell behavior. Rather than simply stimulating immunity, it can help maintain an appropriate balance between protective innate responses and excessive inflammatory T-cell activity. This distinction is particularly important in the intestine, where the immune system must defend against pathogens without continuously attacking the enormous population of harmless microbes.
The intestinal microbiota is highly dynamic. Diet, age, medication use, lifestyle, intestinal transit, inflammation, and host genetics can all alter microbial composition. Vitamin D status represents another factor that may contribute to this microbial environment. Human observational studies have reported associations between vitamin D intake or circulating 25(OH)D concentrations and the abundance of specific bacterial groups. For example, higher vitamin D intake has been associated with increased Prevotella abundance and reduced levels of Haemophilus and Veillonella in some populations. Circulating 25(OH)D has also been positively associated with genera such as Lachnospira and Fusicatenibacter. These findings should not be interpreted as evidence that vitamin D alone determines whether a particular bacterial species is beneficial or harmful. Microbiome composition is influenced by numerous interacting variables. Instead, these observations support the concept that vitamin D status is part of the broader host environment that helps shape microbial communities.
The intestinal barrier is a critical component of the gut-immune axis. It separates the microbial ecosystem from underlying tissues while allowing controlled exchange of nutrients and signaling molecules. Vitamin D signaling through VDR contributes to epithelial homeostasis and the regulation of proteins involved in barrier integrity. It also promotes antimicrobial defenses that help control excessive microbial expansion close to the epithelial surface. This matters because impaired barrier function can increase exposure of immune cells to microbial products. Once this protective boundary becomes compromised, bacterial components can stimulate innate immune receptors and promote inflammatory signaling. Vitamin D therefore influences the microbiota indirectly as well as directly. By maintaining a more stable epithelial environment, it can help prevent the conditions that favor microbial overgrowth and dysbiosis.
Low vitamin D status can disrupt this balance. Experimental studies have linked vitamin D deficiency or impaired VDR signaling with changes in microbial composition, increased intestinal inflammation, and greater susceptibility to intestinal injury. The relationship can become self-reinforcing. A weakened epithelial barrier allows greater microbial stimulation of the immune system. Inflammation can then further modify the intestinal environment, potentially reducing microbial diversity or favoring organisms that tolerate inflammatory conditions. This helps explain why vitamin D status is increasingly considered alongside microbiota and barrier function when investigating chronic intestinal inflammation.
Gut microorganisms do not simply exist alongside vitamin D metabolism; emerging evidence indicates that microbial communities can interact with vitamin D-related metabolic pathways. Certain bacterial strains have been investigated for their potential ability to influence vitamin D metabolism and host vitamin D signaling. For example, experimental work involving Bifidobacterium longum strain FSHHK13M has reported an increase in circulating 1,25(OH)2D levels. The biological significance of these findings is still being investigated. Importantly, the effects observed with a specific bacterial strain should not automatically be generalized to all Bifidobacterium species or to humans in clinical settings. Nevertheless, these observations support an important concept: the gut microbiome may participate in regulating the availability or activity of vitamin D metabolites.
VDR signaling itself can influence the intestinal microbial ecosystem. Changes in VDR activity have been associated with alterations in both the composition and functional characteristics of gut microbial communities. This creates a potentially important feedback relationship. Vitamin D signaling can influence the intestinal environment, while microbial metabolism and microbial-derived signals can affect host pathways involved in vitamin D activity. Rather than viewing vitamin D and the microbiota as two independent variables, researchers increasingly consider them components of a dynamic host-microbe signaling network.
The intestinal barrier may be one of the most important points where vitamin D, microbiota, and immunity converge. A healthy intestinal barrier limits inappropriate contact between microbial products and immune cells. When epithelial integrity is compromised, microbial components can reach deeper tissue layers and activate pattern-recognition receptors. Vitamin D signaling helps maintain this defensive interface through several mechanisms, including regulation of epithelial function and antimicrobial peptide production. At the same time, a balanced microbiota produces metabolites and molecular signals that can support epithelial homeostasis. When either side becomes severely disturbed, the other can be affected. For example, vitamin D insufficiency may weaken aspects of intestinal immune and epithelial regulation. Dysbiosis may then increase microbial stimulation of the mucosa. Persistent immune activation can further impair epithelial function, creating an environment in which dysbiosis and inflammation reinforce one another. This is one reason the gut-immune axis should not be viewed as a simple linear pathway. It behaves more like an interconnected biological system in which changes in one component can propagate through the others.
Inflammatory bowel disease provides one of the clearest clinical contexts in which the relationship between vitamin D, microbiota, and intestinal immunity becomes relevant. IBD includes conditions such as Crohn's disease and ulcerative colitis, in which inappropriate or excessive intestinal immune responses contribute to chronic mucosal inflammation. Changes in gut microbiota and intestinal barrier function are also frequently observed. Clinical evidence has found that lower circulating 25(OH)D concentrations are associated with several unfavorable IBD-related outcomes. A meta-analysis involving more than 8,000 individuals with IBD reported associations between low 25(OH)D and greater disease activity, mucosal inflammation, poorer quality of life, and increased risk of clinical relapse. These findings do not establish that low vitamin D directly causes IBD progression. Inflammation, reduced dietary intake, malabsorption, limited sunlight exposure, and other disease-related factors can all contribute to low vitamin D status. The relationship is therefore likely to be bidirectional.
VDR signaling provides a mechanistic connection between vitamin D status and intestinal inflammation. Vitamin D-related pathways can influence innate immune signaling, including pathways involving NOD2 and NF-κB, which are important regulators of inflammatory responses to microbial signals. Under appropriate conditions, these pathways help the intestine respond to microorganisms without producing uncontrolled inflammation. Disruption of VDR signaling or inadequate vitamin D availability may alter this regulatory balance. This is particularly relevant to IBD because intestinal inflammation is closely connected to microbial composition, epithelial permeability, and innate immune activation.
This is one of the most interesting questions emerging from current research. If vitamin D affects intestinal microbial communities and the microbiota can influence vitamin D metabolism, correcting vitamin D insufficiency could theoretically modify the gut-immune environment. Some human studies have reported changes in microbiota composition following vitamin D supplementation, but the results are not sufficiently consistent to conclude that vitamin D supplementation produces a predictable microbiome profile in everyone. Several factors may explain these differences. Baseline vitamin D status, dosage, duration, diet, age, medication use, geographic location, underlying disease, and the starting microbiome can all influence the response. Therefore, vitamin D should not currently be viewed as a universal microbiome-modifying intervention. Its most established role remains assessment and management of vitamin D status, while microbiome-related effects represent an active area of investigation.
The gut-microbiota-vitamin D relationship is highly context-dependent. Measuring only serum 25(OH)D provides useful information about systemic vitamin D status, but it does not capture the entire biological pathway. A more comprehensive research approach may consider serum 25(OH)D together with vitamin D metabolites, VDR expression or signaling, intestinal barrier markers, microbial composition, microbial functional pathways, and inflammatory biomarkers. This distinction is particularly important when interpreting microbiome studies. A difference in bacterial abundance does not necessarily mean that the bacterium is responsible for a change in vitamin D status. Conversely, an association between low 25(OH)D and dysbiosis does not prove that vitamin D deficiency is the initiating event. Longitudinal and mechanistic studies are therefore valuable for determining directionality and identifying which microbial taxa, metabolites, and host pathways are most biologically important.
The emerging picture is that 25(OH)D and the gut microbiota participate in a two-way regulatory network. Vitamin D is metabolically activated and signals through VDR in intestinal and immune cells. This signaling can support antimicrobial defense, epithelial barrier integrity, and controlled immune responses, thereby influencing the environment in which intestinal microorganisms live. At the same time, gut microorganisms may interact with vitamin D metabolism and host VDR-related pathways. Changes in microbial communities can therefore potentially alter vitamin D activity, while changes in vitamin D signaling can reshape microbial ecology. When this equilibrium is disturbed, dysbiosis, barrier dysfunction, and inflammation may reinforce each other. This mechanism is especially relevant to chronic intestinal inflammatory conditions such as IBD.
The relationship between vitamin D and the microbiome is moving beyond the traditional question of whether someone has "enough vitamin D." Researchers are increasingly interested in how vitamin D metabolites, VDR signaling, microbial metabolites, epithelial barrier function, and immune responses interact as a complete biological system. Future studies may help determine whether particular microbial signatures predict responses to vitamin D supplementation, whether specific probiotic strains can influence vitamin D metabolism, and whether combined strategies targeting nutritional status, microbiota, and intestinal inflammation can provide more effective disease management. For now, the strongest conclusion is not that vitamin D supplementation can independently correct dysbiosis, but that vitamin D status is biologically connected to intestinal microbial and immune homeostasis. Understanding that connection may provide new opportunities for studying inflammation, mucosal immunity, and microbiome-associated disease.
The interaction between gut microbiota and 25-OH vitamin D is a dynamic component of the gut-immune axis. Vitamin D signaling through VDR supports antimicrobial defense, epithelial barrier integrity, and immune regulation, while the gut microbiota can influence vitamin D metabolism and signaling. These interactions create a feedback network that helps maintain intestinal homeostasis. When vitamin D status, microbial balance, or barrier integrity is disrupted, inflammatory signaling may become amplified. Evidence from IBD and experimental models highlights why this relationship deserves continued attention. Rather than treating vitamin D and the microbiome as separate research topics, studying them together may provide a more complete understanding of how nutritional status, microbial ecology, mucosal immunity, and chronic inflammation intersect.
25-OH vitamin D may influence gut microbiota indirectly through vitamin D receptor (VDR) signaling, intestinal barrier maintenance, and antimicrobial peptide production. These effects can help regulate the intestinal environment and may influence the abundance of certain bacterial groups.
Yes. Emerging evidence suggests that gut microorganisms may interact with vitamin D metabolism and host VDR signaling. Certain bacterial strains may influence vitamin D metabolite activity, indicating that the relationship between vitamin D and the microbiome is potentially bidirectional.
Low vitamin D status has been associated with impaired intestinal barrier function, altered microbial composition, and increased inflammatory activity. In conditions such as inflammatory bowel disease, lower 25(OH)D concentrations are also associated with greater disease activity and other unfavorable clinical outcomes.
Some studies have reported changes in gut microbial composition following vitamin D supplementation, but the results are not yet consistent enough to conclude that supplementation produces the same microbiome changes in everyone. Baseline vitamin D status, diet, disease status, medications, and individual microbiota can all affect the response.
The vitamin D receptor (VDR) connects vitamin D signaling with intestinal barrier function, antimicrobial defense, microbial homeostasis, and immune regulation. Altered VDR signaling may contribute to changes in the gut microbiota and inflammatory responses, making it an important pathway for gut-immune research.
References
| Target | Cat. No. | Product Name | Host | Application | |
| 25-OH Vitamin D | DMABA-JX119 | Rabbit Anti-25 OH Vitamin D monoclonal antibody, clone S594L4 | Rabbit | ELISA, LFIA, CLIA | Inquiry |
| DMABA-JX120 | Rabbit Anti-25 OH Vitamin D monoclonal antibody, clone S595K5 | Rabbit | ELISA, LFIA, CLIA | Inquiry | |
| DMAB-JXL2399 | Goat Anti-25-OH VD2/VD3 Monoclonal Antibody, clone 5C3 | CHO | ELISA, CLIA, LFIA | Inquiry | |
| DMAB2913 | Mouse Anti-25 OH Vitamin D3 monoclonal antibody, clone L35235N | Mouse | ELISA | Inquiry | |
| DMAB2914 | Mouse Anti-25 OH Vitamin D3 Monoclonal antibody, clone C2531M | Mouse | ELISA | Inquiry | |
| CABT-L1343W | Humanized Anti-Human 25-OH-VD Monoclonal antibody, clone 214I2T | Humanized | LFIA, CLIA | Inquiry | |
| CABT-L1344W | Humanized Anti-Human 25-OH-VD Monoclonal antibody, clone 214I5 | Humanized | PETIA | Inquiry |
| Target | Cat. No. | Product Name | Conjugate | Application | |
| 25-OH Vitamin D | DAG-WT2678 | 25-hydroxyvitamin D control | Unconjugated | Calibration, Control | Inquiry |
| DAG-WT2679 | 25-hydroxyvitamin D2 control | Unconjugated | Calibration, Control | Inquiry | |
| DAG-WT2680 | 25-hydroxyvitamin D3 control | Unconjugated | Calibration, Control | Inquiry | |
| DAG03219 | 25-OH Vitamin D3 [BSA] | BSA | ELISA, LFIA | Inquiry | |
| DAGA-126H | 25-OH Vitamin D [HRP] | HRP | ELISA | Inquiry | |
| DAGA-126K | 25-OH Vitamin D [KLH] | KLH | Immunogen | Inquiry | |
| DAG-WT6032B | 25-OH Vitamin D2 [BSA] | BSA | ELISA, LFIA | Inquiry |
| Target | Cat. No. | Product Name | Species Reactivity | Application | Detection Sample | |
| 25-OH Vitamin D | DEIA4458 | 25-OH Vitamin D ELISA Kit | Human | Quantitative | Serum, Plasma | Inquiry |
| DEIA1733 | 25 (OH) Vitamin D ELISA Kit | Human | Quantitative | plasma, serum | Inquiry | |
| DEIA002J | 25-OH Vitamin D direct (1-point calibration) ELISA Kit | Human | Quantitative | serum | Inquiry | |
| DEIA003J | 25-OH Vitamin D direct day ELISA Kit | Human | Quantitative | serum, fresh plasma | Inquiry | |
| DEIA004J | 25-OH Vitamin D direct ELISA Kit | Human | Quantitative | serum, fresh plasma | Inquiry | |
| DEIA005J | 25-OH Vitamin D Xpress ELISA Kit | Human | Quantitative | serum, fresh EDTA plasma | Inquiry | |
| DEIA006J | 25-OH Vitamin D ELISA Kit | Human | Quantitative | serum, plasma | Inquiry | |
| DEIA2219 | 25-OH Vitamin D (total) ELISA Kit | Human | Quantitative | Serum | Inquiry | |
| DEIA-BJ574-1 | Human 25 (OH) D3 ELISA kit | Human | Quantitative | Serum, plasma and other biological fluids. | Inquiry | |
| DEIA-BJ2145 | Rat 25 Hydroxy Vitamin D3 ELISA Kit | Rat | Quantitative | Serum, plasma, cell culture supernatants, body fluid and tissue homogenate | Inquiry | |
| DEIA-NS2651 | 25OH-D (Total 25-OH Vitamin D) ELISA Kit | Universal | Quantitative | Serum, plasma, cellculture supernatant and other biological samples. | Inquiry | |
| DEIA-BJ648 | Human 25 Hydroxy Vitamin D ELISA kit | Human | Quantitative | biological fluids. | Inquiry |
Loading ......
